In this regard, the MARIPOSA and MARIPOSA-2 trials represent a milestone in the field of EGFR-mutated NSCLC, leading to the approval of the combination of a third-generation EGFR TKI and the bispecific EGFR-MET antibody amivantamab, in both first- and second-line settings. The gene discussed is MET; the disease is non-small cell lung carcinoma.